New Rhein is a global venture capital manager founded in 2010. The Firm is a Limited Liability Company formed under the laws of Delaware and is wholly owned by Dr. Nayan Gregory Parekh. Dr. Parekh, also known as Greg, is the Founder of the Firm and a Managing Partner. New Rhein is managed by three Managing Partners: Dr. Parekh, Mr. Subhanu Saxena, and Dr. Ivan Gergel, who is also the Firm’s Chief Medical Officer. The Firm is headquartered in Philadelphia, PA and has offices in Mechelen, Belgium and London, UK. Further explanation of the Firm’s Belgian and UK affiliates can be found in Item 10 below. New Rhein has an advisory board comprising professionals in the healthcare industry which assists in the identification of potential investments, due diligence, and strategic advice. The Firm also has a roster of “Executives in Residence,” a network of healthcare professionals who may from time to time be available to provide consulting services to New Rhein and/or serve as officers and/or directors of companies held in New Rhein’s portfolios. None of the advisory board members nor the Executives in Residence are employees of the Firm. New Rhein may from time to time employ certain individuals denoted as “Operating Executives” who may provide services as consultants, officers and/or directors to companies in New Rhein Funds’ portfolios. New Rhein provides discretionary investment management to its clients, including to clients organized as private investment funds (each a “Fund” and, collectively, the “New Rhein Funds” or the “Funds”), and may also provide advisory and due diligence services to clients that are separate from its investment management activities. The Funds invest through negotiated transactions in operating entities, generally referred to herein as “portfolio companies.” New Rhein’s investment advisory services to the Funds consist of identifying and evaluating investment opportunities, negotiating the terms of investments, managing and monitoring investments and achieving dispositions for such investments. From time to time, where such investments consist of portfolio companies, the senior principals or other personnel of New Rhein or its affiliates generally serve on such portfolio companies’ respective boards of directors or otherwise act to influence management of portfolio companies in which the Funds have invested. New Rhein’s advisory services to the Funds and the terms thereof are detailed in the relevant limited partnership agreement of a Fund as well as an investment management agreement between New Rhein and the General Partner of the relevant Fund (the “General Partners”

and each, a “General Partner”) and are further described below. Investors in the Funds participate in the overall investment program for the applicable Fund, but in exceptional circumstances may be excused from a particular investment due to legal, regulatory or other agreed-upon circumstances pursuant to the relevant partnership agreement; for the avoidance of doubt, such arrangements generally do not and will not create an adviser-client relationship between New Rhein and any investor. The relevant partnership agreement of a Fund and other Fund related agreements and documents such as investor presentations are sometimes referred to herein as a Fund’s “offering documents.” Additionally, from time to time and as permitted by the relevant partnership agreement, New Rhein expects to provide (or agree to provide) co-investment opportunities (including the opportunity to participate in co-invest vehicles) to certain investors or other persons or affiliates, including sponsors, market participants, finders, consultants and other service providers, New Rhein’s advisory board members and/or certain other persons associated with New Rhein and/or its affiliates. Such co- investments typically involve investment and disposal of interests in the applicable portfolio company at the same time and on the same terms as the Fund making the investment. However, on rare occasions such as when a co-investor must form an investment vehicle and is not able to do so prior to the closing of an investment transaction, a co-investor or co-invest vehicle (including a co-investing Fund) may purchase a portion of an investment from one or more Funds after such Funds have consummated their investment in the portfolio company (also known as a post-closing sell-down or transfer), which generally will have been funded through Fund investor capital contributions and/or use of a Fund credit facility. Any such purchase from a Fund by a co-investor or co-invest vehicle would generally occur shortly after the Fund’s completion of the investment to avoid any changes in valuation of the investment. Where appropriate, and in New Rhein’s sole discretion, New Rhein reserves the right to charge interest on the purchase to the co-investor or co-invest vehicle (or otherwise equitably to adjust the purchase price under certain conditions), and to seek reimbursement to the relevant Fund for related costs. However, to the extent such amounts are not so charged or reimbursed, they generally will be borne by the relevant Fund. As of December 31, 2023, the Firm managed $229,555,832 in regulatory assets under management on a discretionary basis.